Treatment of toxic adenoma and toxic multinodular goiter
- Douglas S Ross, MD
Douglas S Ross, MD
- Section Editor — Thyroid Disease
- Professor of Medicine
- Harvard Medical School
Toxic adenoma and toxic multinodular goiter (MNG) are common causes of hyperthyroidism, second in prevalence only to Graves' disease. The prevalence of toxic nodular goiter increases with age and in the presence of iodine deficiency, and may therefore be more common than Graves’ disease in older populations in regions of iodine deficiency. Toxic adenoma and MNG are the result of focal and/or diffuse hyperplasia of thyroid follicular cells whose functional capacity is independent of regulation by TSH. Twenty to 80 percent of toxic adenomas and some nodules of multinodular goiters have somatic mutations of the thyrotropin (TSH) receptor gene that confers autonomous hyperactivity [1,2].
Following a brief discussion of the diagnosis and evaluation of toxic adenoma and MNG, the treatment of these disorders will be presented here. Other disorders that cause hyperthyroidism, the clinical manifestations and diagnosis of hyperthyroidism, and treatment of Graves’ hyperthyroidism are reviewed separately. (See "Disorders that cause hyperthyroidism" and "Overview of the clinical manifestations of hyperthyroidism in adults" and "Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes" and "Diagnosis of hyperthyroidism" and "Hyperthyroidism during pregnancy: Treatment" and "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment".)
DIAGNOSIS AND EVALUATION
Because the treatment of hyperthyroidism differs according to the etiology, the correct diagnosis must be made before therapy is instituted. (See "Diagnosis of hyperthyroidism".) The diagnosis of hyperthyroidism is usually evident in patients with unequivocal clinical and biochemical manifestations of the disease. Other patients have fewer and less obvious clinical signs, but definite biochemical hyperthyroidism (low serum TSH and high free T4 and/or T3 concentrations). Still others have low serum TSH concentrations (<0.5 mU/mL) but normal serum free thyroxine (T4) and triiodothyronine (T3) concentrations, a constellation of biochemical findings defined as subclinical hyperthyroidism. (See "Subclinical hyperthyroidism".)
Thyroid scintigraphy — Once the diagnosis of hyperthyroidism has been established, the cause of the hyperthyroidism should be distinguished by the findings on the 24-hour radioiodine uptake and scan. Women of childbearing age should have a negative pregnancy test prior to undergoing radioactive iodine scanning.
●A classic clinical presentation for toxic adenoma is a hyperthyroid patient with a palpable thyroid nodule that corresponds to an area of increased radioiodine concentration on thyroid scintigraphy; there should also be suppression of radioiodine uptake in surrounding and contralateral tissue (picture 1).
- Russo D, Arturi F, Suarez HG, et al. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1996; 81:1548.
- Tonacchera M, Chiovato L, Pinchera A, et al. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 1998; 83:492.
- Nygaard B, Hegedüs L, Ulriksen P, et al. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999; 159:1364.
- Cerci C, Cerci SS, Eroglu E, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med 2007; 53:157.
- Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995; 273:808.
- Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93:61.
- Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330:1731.
- Nygaard B, Hegedüs L, Nielsen KG, et al. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 1999; 50:197.
- Kahraman D, Keller C, Schneider C, et al. Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy. Clin Endocrinol (Oxf) 2012; 76:297.
- Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann Intern Med 1984; 101:488.
- Ceccarelli C, Bencivelli W, Vitti P, et al. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf) 2005; 62:331.
- Nygaard B. Changes in the thyroid technetium-99m scintigram after antithyroid and subsequent radioiodine treatment for solitary autonomous nodules. Thyroid 1998; 8:223.
- Porterfield JR Jr, Thompson GB, Farley DR, et al. Evidence-based management of toxic multinodular goiter (Plummer's Disease). World J Surg 2008; 32:1278.
- Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.
- Walter MA, Christ-Crain M, Schindler C, et al. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 2006; 33:730.
- Wu SY, Shyh TP, Chopra IJ, et al. Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J Clin Endocrinol Metab 1982; 54:630.
- Papini E, Panunzi C, Pacella CM, et al. Percutaneous ultrasound-guided ethanol injection: a new treatment of toxic autonomously functioning thyroid nodules? J Clin Endocrinol Metab 1993; 76:411.
- Del Prete S, Russo D, Caraglia M, et al. Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up. Clin Radiol 2001; 56:895.
- Guglielmi R, Pacella CM, Bianchini A, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid 2004; 14:125.
- Janowitz P, Ackmann S. [Long-term results of ultrasound-guided ethanol injections in patients with autonomous thyroid nodules and hyperthyroidism]. Med Klin (Munich) 2001; 96:451.
- Monzani F, Caraccio N, Goletti O, et al. Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. Clin Endocrinol (Oxf) 1997; 46:9.
- Zingrillo M, Torlontano M, Ghiggi MR, et al. Radioiodine and percutaneous ethanol injection in the treatment of large toxic thyroid nodule: a long-term study. Thyroid 2000; 10:985.
- Døssing H, Bennedbaek FN, Bonnema SJ, et al. Randomized prospective study comparing a single radioiodine dose and a single laser therapy session in autonomously functioning thyroid nodules. Eur J Endocrinol 2007; 157:95.
- Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery 2002; 132:916.
- Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364:542.
- Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid 2004; 14:933.
- DIAGNOSIS AND EVALUATION
- Thyroid scintigraphy
- Thyroid ultrasound
- INDICATIONS FOR TREATMENT
- THERAPEUTIC OPTIONS
- Radioiodine therapy
- Thionamide administration
- - Pretreament before radioiodine or surgery
- - Long-term administration
- Administration of iodinated radiocontrast agents or iodine
- Ethanol injection
- Laser therapy
- Choice of therapy
- Monitoring after therapy
- - Radioiodine
- - Surgery
- - Persistent or recurrent disease
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS